Inovio highlights key updates on phase 3 program for vgx-3100, its dna-based immunotherapy for the treatment of cervical hsil caused by hpv-16 and/or hpv-18

Plymouth meeting, pa., dec. 14, 2021 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on bringing to market precisely designed dna medicines to help protect people from infectious diseases and treat cancer and hpv-associated diseases, today announced updates on the phase 3 program for vgx-3100 for hpv-associated cervical high-grade squamous intraepithelial lesions (hsil), including a one-year follow-up of efficacy and safety data in participants from reveal1, completing enrollment in reveal2, and advancing its pre-treatment biomarker candidate for vgx-3100 to be further developed with qiagen.
INO Ratings Summary
INO Quant Ranking